BIVIW BioVie Inc. - Warrant
0.2999USD0.00%Mkt Cap: —P/E: —8d ago
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that i…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-22.07M USD
Revenue/Share—
Last Price0.2999 USD
Fiscal Year End—
MR Quarter—
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.24
EPS (TTM)—
EPS (Forward)—
52W Range
0.130026% of range0.7900
52W High0.7900 USD
52W Low0.1300 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-214.92%
ROA-154.89%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.02M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-8.70M USD
Net Debt/EBITDA0.39
Balance Sheet
Debt/Equity0.03
Current Ratio3.59
Quick Ratio2.93
Book Value/Sh1.36 USD
Cash/Share1.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float7.48M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta0.73
S&P 52W Chg15.78%
Avg Vol (30d)193.96K
Avg Vol (10d)—
Technical Indicators
RSI (14)47.1
MACD-0.0072
MACD Signal-0.0061
MACD Hist.-0.0012
BB Upper0.4067 USD
BB Middle0.3121 USD
BB Lower0.2175 USD
BB Width60.65%
ATR (14)0.0690 USD
Vol Ratio (20d)0.02x